FOLFOX4s

Phase 3Small molecule

FOLFOX4s is one of 5 small molecule programs targeting Locally Advanced Rectal Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Rectal AdenocarcinomaNot yet recruiting

Locally Advanced Rectal AdenocarcinomaPhase 3

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Locally Advanced Rectal Adenocarcinoma

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 2

1 2

Opdivo

Bristol-Myers Squibb

Phase 2

1 3

FOLFOX4s

UUNICANCER

Phase 3

1 4

Consolidation Therapy

IInstitute of Hematology & Blood Diseases Hospital, China

Phase 1

1 5

Papaverine

WWestern Galilee Hospital-Nahariya

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 3Not yet recruiting

Locally Advanced Rectal Adenocarcinoma

NCT07118800

Clinical

Trials by Indication[1]

Locally Advanced Rectal Adenocarcinoma1 trial

Randomized Phase III Study Evaluating Two Treatment Strategies for Locally Advanced Rectal Cancer in Patients ≥75 Years Old

Not yet recruiting·UUNICANCER·Phase 3·NCT07118800·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FOLFOX4s. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFOX4s compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFOX4s. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UNICANCER company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUNICANCER

FOLFOX4s

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Locally Advanced Rectal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News